Dual effects of an anti-CD147 antibody for Esophageal cancer therapy.

Conclusions: The in vitro and in vivo study demonstrated dual effects of Metuzumab in effectively mediating ADCC by activating effector cells, and inhibiting metastasis of esophageal cancer through blockade the function of CD147, providing justification for moving Metuzumab forward to clinical development in esophageal cancer.
PMID: 31411555 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - August 13, 2019 Category: Cancer & Oncology Authors: Wang M, Zhang S, Sun Q, Yang X, Wang Y, Shang R, Zhu Y, Yao H, Li Y Tags: Cancer Biol Ther Source Type: research